American Heart Association

NEW ORLEANS — Healio.com/HemOnc is reporting live from the ASH Late-Breaking Abstracts, expected to highlight the latest advances in the diagnosis, treatment and prevention of blood disorders, as well as new breakthroughs in research.

Beginning this week, the HemOnc Today and Healio.com/Hematology-Oncology team will present live coverage from the 2013 San Antonio Breast Cancer Symposium, an annual meeting presented by the Cancer Therapy & Research Center at UT Health Science Center San Antonio, the American Association for Cancer Research and Baylor College of Medicine.

DALLAS — A common question in medicine is: What therapies improve mortality in patients with HF with reduced ejection fraction? As a current cardiology fellow, I have “grown up” in an era in which medical students and residents are able to rapidly rattle off the many correct answers to this common question on rounds. One of my favorite questions to ask instead is: What therapies improve mortality in patients with HF with preserved ejection fraction? Unfortunately, this question has stumped medical students and HF specialists alike for many years.

DALLAS — CV endurance in children has significantly declined since 1964, according to research presented at AHA 2013.

DALLAS — Aspirin intake at bedtime did not lead to reduced BP when compared with aspirin intake in the morning, but it was associated with greater inhibition of platelet reactivity during morning hours, according to data presented at AHA 2013.

DALLAS — Leaders of the teams that developed the recently released American College of Cardiology/American Heart Association joint clinical practice guidelines for the prevention of CVD defended their work from criticism but promised evidence-based refinements, if necessary, during a forum at AHA 2013.

DALLAS — A paclitaxel-eluting bioabsorbable magnesium scaffold was associated with an excellent safety profile at 3 years and significantly improved efficacy at 12 months, and did not lead to death or scaffold thrombosis at follow-up, according to a researcher from the BIOSOLVE-I trial.

DALLAS — A paclitaxel-eluting bioabsorbable magnesium scaffold was associated with an excellent safety profile at 3 years and significantly improved efficacy at 12 months, and did not lead to death or scaffold thrombosis at follow-up, according to a researcher from the BIOSOLVE-I trial.

DALLAS — Valsartan reduced carotid artery wall thickness and decreased plaque thickness at 24 months in patients with carotid atherosclerosis, according to results from a new report presented at AHA 2013.

DALLAS — New study results indicate that older adults who smoked fewer than three packs of cigarette per day for up to 10 years or fewer than one pack per day for 30 years lowered their risks for HF or death related to HF, MI and stroke to the same level as never-smokers within 15 years after quitting.